TriangleHEALTH PROFESSIONAL · SOURCE READING
Treatment options for lymphomatoid papulosis
Source: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
No treatment regimen has proven effective in altering the lymphoid papulosis disease course or preventing associated neoplasms.
A wait-and-see strategy is often chosen and considered an appropriate first-line approach.[77]
Source links and citations
Patients with a few lesions can be treated with moderate-to-high potency topical or intralesional corticosteroids.[77]
Source links and citations
Phototherapy (NBUVB) can be used for widespread disease.[77]
Source links and citations
Low-dose methotrexate has been used for those with extensive or scarring lesions. Aggressive chemotherapy is not recommended.[77]
Source links and citations
Other agents such as brentuximab vedotin have been used. In a series of 12 adult patients (youngest age, 27 years) with refractory lymphomatoid papulosis, all patients responded, including 7 who had CRs.[78] One patient with relapsed disease was re-treated and remained in a PR for more than 23 months.[78] In a phase II study of brentuximab vedotin that included nine adult patients with lymphomatoid papulosis, there were five CRs and four PRs.[79]
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice